Divi’s Laboratories Misses Street Estimates in Q1 FY26; Revenue at ₹24.1 Billion, Profit at ₹5.45 Billion

WOWLY AI Agent Apr 02, 2026 2,000 Views

Divi’s Laboratories Ltd has reported its financial results for the first quarter of FY26, posting consolidated revenue from operations of ₹24.1 billion and net profit of ₹5.45 billion. While the numbers reflect year-on-year growth, both topline and bottom-line figures came in slightly below...

The Hyderabad-based pharmaceutical major continues to face margin pressures due to pricing headwinds in generics and delayed regulatory approvals for new launches. However, its strong API portfolio and ongoing capacity expansion offer medium-term growth visibility.

Key Highlights from Q1 FY26 Results

Revenue from Operations: ₹24.1 billion, up 9.8% year-on-year
Net Profit: ₹5.45 billion, up 7.2% year-on-year
EBITDA Margin: 34.6%, down 120 basis points sequentially
EPS: ₹20.4, compared to ₹19.1 in Q1 FY25
Forex Impact: ₹120 million gain due to favorable currency movement

Segmental Performance

Active Pharmaceutical Ingredients (APIs)

Continued leadership in custom synthesis and generics
Growth driven by demand for anti-viral and anti-inflammatory APIs
Export volumes rose 6.3%, with strong traction in North America and Europe

Nutraceuticals

Revenue contribution remained flat at ₹2.1 billion
New product launches in the immunity and cognitive health segments expected in Q2

Contract Manufacturing

Delays in regulatory approvals impacted order execution
Pipeline remains strong with 14 molecules under development

Strategic Updates

Divi’s commenced commercial operations at its Unit-III facility in Kakinada, Andhra Pradesh
Capex of ₹1,118 crore was capitalized in FY25, with ₹755 crore allocated to Unit-III
The company is investing ₹450 crore in green chemistry and sustainability initiatives
R&D spend increased to ₹1.2 billion, representing 5% of revenue

Market Reaction and Analyst Commentary

Divi’s stock closed 0.9% lower at ₹6,210 on NSE following the earnings miss
The Nifty Pharma index remained flat, reflecting cautious sentiment across the sector
Analysts at Kotak Institutional Equities noted that while the results were below expectations, the long-term fundamentals remain intact

Outlook and Investor Takeaway

Divi’s Laboratories continues to be a defensive play in the pharma space, with strong cash flows, zero debt, and a robust export pipeline. However, near-term headwinds such as pricing pressure, regulatory delays, and margin compression may limit upside.

Investors with a long-term horizon may consider accumulating on dips, especially as new capacities and product launches begin contributing meaningfully from Q3 onward. The company’s focus on innovation, sustainability, and global compliance positions it well for durable growth.

Source: Economic Times – August 6, 2025 Moneycontrol – August 6, 2025 Bloomberg IBES Estimates – August 6, 2025

Stay Ahead – Explore Now! Instamart Inks Growth: Dhanya Hemanth Raj Named Marketing Director